Arthroplasty Today 1 (2015) 117e120
Contents lists available at ScienceDirect
Arthroplasty Today journal homepage: http://www.arthroplastytoday.org/
Original research
Periarticular injection of liposomal bupivacaine in total knee arthroplasty Bradley T. Webb, MD, J. Reid Spears, BS, Langan S. Smith, BS, Arthur L. Malkani, MD * KentuckyOne Health, Louisville, KY, USA
a r t i c l e i n f o
a b s t r a c t
Article history: Received 21 July 2015 Received in revised form 3 September 2015 Accepted 5 September 2015 Available online 12 October 2015
The purpose of this study was to determine whether the use of a periarticular injection using liposomal bupivacaine could decrease pain and improve outcomes after total knee arthroplasty. Fifty consecutive patients received no periarticular injections (group A). Another 50 consecutive patients received a periarticular injection of liposomal bupivacaine (group B). There were no differences in the groups with respect to gender, age, body mass index (BMI), or comorbidities. There was a significant reduction in the amount of narcotics used in the liposomal bupivacaine group (60.97-mg oral morphine equivalent vs 89.74 mg, P ¼ 0.009). Patients in group B with a BMI
Contents lists available at ScienceDirect
Arthroplasty Today journal homepage: http://www.arthroplastytoday.org/
Original research
Periarticular injection of liposomal bupivacaine in total knee arthroplasty Bradley T. Webb, MD, J. Reid Spears, BS, Langan S. Smith, BS, Arthur L. Malkani, MD * KentuckyOne Health, Louisville, KY, USA
a r t i c l e i n f o
a b s t r a c t
Article history: Received 21 July 2015 Received in revised form 3 September 2015 Accepted 5 September 2015 Available online 12 October 2015
The purpose of this study was to determine whether the use of a periarticular injection using liposomal bupivacaine could decrease pain and improve outcomes after total knee arthroplasty. Fifty consecutive patients received no periarticular injections (group A). Another 50 consecutive patients received a periarticular injection of liposomal bupivacaine (group B). There were no differences in the groups with respect to gender, age, body mass index (BMI), or comorbidities. There was a significant reduction in the amount of narcotics used in the liposomal bupivacaine group (60.97-mg oral morphine equivalent vs 89.74 mg, P ¼ 0.009). Patients in group B with a BMI
